Longbow et al. invest in Domainex

Domainex has secured financing to further develop its combinatorial domain hunting (CDH) technology, which allows the company to deliver protein constructs that are soluble, stable and produced in high-yield - thereby opening up the path to high throughput screening, structural biology or anitbody production. The new funds will allow the business to advance its internal pipeline of oncology targets.

The two-stage funding round is expected to take Domainex to a point where it can close a number of corporate collaborations and deals on its novel targets for cancer. The company was founded in 2002 and has offices in Cambridge and London.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• UK / Ireland
• Healthcare